Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven(®)) utilization at a large academic medical center

BACKGROUND: Recombinant factor VIIa (rFVIIa) (Novoseven®) is utilized for the reversal of anticoagulation-associated bleeding and refractory bleeding in cardiac surgery. In August 2015, rFVIIa was transferred from the blood bank to the pharmacy at New York University (NYU) Langone Health. Concordant...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsh, Kassandra, Green, David, Raco, Veronica, Papadopoulos, John, Ahuja, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249557/
https://www.ncbi.nlm.nih.gov/pubmed/32449469
http://dx.doi.org/10.1177/1753944720924255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249557/
https://www.ncbi.nlm.nih.gov/pubmed/32449469
http://dx.doi.org/10.1177/1753944720924255

Ejemplares similares